Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to che...
Radio and PodcastLive Radio & Podcasts
Science & Medicine
GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing C...
Episodes
20 of 300 episodes
Management of Rare Kidney Tumors
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer pat...
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Treatment for Kidney Cancer
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatment...
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a sta...
How is the Heng Criteria Applied to Kidney Cancer Patients?
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses...
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doc...
What is PD1 and PDL1 in Kidney Cancer?
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight k...
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potent...
No Clear Answer for Non-Clear Cell Kidney Cancer
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are...
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the...
Treating Newly Diagnosed Kidney Cancer
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
MET-Amplified Lung Cancer: A New Target for XALKORI?
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patient...
The Hottest Thing in Late Stage Kidney Cancer
Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particula...
The Promise of PD1 Inhibitors in Kidney Cancer
Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.
FGFR and Its Role in Treating Squamous Cell Lung Cancer
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks abou...
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.
What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she...
What Is Non-Clear Cell Kidney Cancer?
Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.